192 related articles for article (PubMed ID: 35896284)
1. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
2. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
3. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
[TBL] [Abstract][Full Text] [Related]
4. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
Coutzac C; Adam J; Soularue E; Collins M; Racine A; Mussini C; Boselli L; Kamsukom N; Mateus C; Charrier M; Cassard L; Planchard D; Ribrag V; Fizazi K; Loriot Y; Lepage P; Scoazec JY; Robert C; Carbonnel F; Chaput N
J Crohns Colitis; 2017 Oct; 11(10):1238-1246. PubMed ID: 28967957
[TBL] [Abstract][Full Text] [Related]
5. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
[TBL] [Abstract][Full Text] [Related]
6. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
[TBL] [Abstract][Full Text] [Related]
7. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract][Full Text] [Related]
11. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
[TBL] [Abstract][Full Text] [Related]
12. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
14. Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002190
[No Abstract] [Full Text] [Related]
15. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
16. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
17. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
[TBL] [Abstract][Full Text] [Related]
19. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD; Michaels T; Bellone S; Hartwich TMP; Bonazzoli E; Iwasaki A; Song E; Santin AD
Cancer Discov; 2023 Feb; 13(2):312-331. PubMed ID: 36301137
[TBL] [Abstract][Full Text] [Related]
20. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
